Relationship between metalloproteinase-9 (MMP-9) expression and clinicopathology in colorectal cancer: a cross-sectional study.
cancer staging
colorectal cancer
cross-sectional study
histopathological grade
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
06
09
2022
accepted:
13
05
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
According to the WHO's GLOBOCAN database, ~1,931,590 new colorectal cancer (CRC) cases and 915,607 CRC-related deaths occurred in 2020. The incidence of CRC in Indonesia is 8.6%, making it the fourth most common cancer. With CRC, matrix metalloproteinase-9 (MMP-9) has a role in tumour development and progression, such that patients with a higher MMP-9 expression had poorer survival. This study aimed to analyze the relationship between MMP-9 expression and clinicopathology in CRC patients. This was an analytic observational study with a cross-sectional research design. It was conducted from November 2021 to June 2022 with 52 patient tissue samples: these were subjected to MMP-9 immunohistochemistry stain, with the GeneTex (Irvine) MMP-9 monoclonal antibody. Patient data were collected with clinical variables based on medical records and histopathological examination by anatomy pathologists. Primary tumour location, cancer staging, and histopathology grading were associated with MMP-9 ( A significant relationship existed of primary tumour location, cancer staging, and histopathology grading with MMP-9 expression in CRC patients. MMP-9 expression could be a useful indicator for the clinical assessment of tumour biologic behaviour and prognosis in CRC patients.
Identifiants
pubmed: 37663709
doi: 10.1097/MS9.0000000000000892
pii: AMSU-D-22-01996
pmc: PMC10473300
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4277-4282Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Références
Cancer Res. 1998 Mar 1;58(5):1048-51
pubmed: 9500469
World J Surg Oncol. 2014 Jan 29;12:24
pubmed: 24476461
Am J Pathol. 1993 Feb;142(2):359-65
pubmed: 8434636
Eur J Med Chem. 2020 May 15;194:112260
pubmed: 32224379
Ann Med Surg (Lond). 2021 Dec 30;74:103211
pubmed: 35059192
J Pathol. 2015 Nov;237(3):273-81
pubmed: 26174849
Clin Exp Metastasis. 1996 Jan;14(1):3-11
pubmed: 8521614
World J Gastroenterol. 2015 Jun 7;21(21):6470-8
pubmed: 26074686
J Natl Cancer Inst. 2010 Nov 3;102(21):1628-36
pubmed: 20975037
J Int Med Res. 2021 May;49(5):3000605211012570
pubmed: 33942633
Eur J Cancer. 2017 Oct;84:69-80
pubmed: 28787661
Ann Diagn Pathol. 2019 Jun;40:161-165
pubmed: 31100646
Anticancer Res. 1999 Jul-Aug;19(4B):2929-38
pubmed: 10652575
Cancers (Basel). 2014 Jan 27;6(1):240-96
pubmed: 24473089
JAMA Oncol. 2017 Feb 01;3(2):211-219
pubmed: 27787550
JAMA. 2008 Dec 17;300(23):2765-78
pubmed: 19088354
Carcinogenesis. 2014 Jul;35(7):1516-22
pubmed: 24648381
Am J Prev Med. 2014 Mar;46(3 Suppl 1):S7-15
pubmed: 24512933
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Rep. 2015 Aug 12;5:13030
pubmed: 26264519
Cancer Invest. 2010 Jan;28(1):38-43
pubmed: 20001295
Cancer Res. 2000 Oct 1;60(19):5410-3
pubmed: 11034081
Clin Transl Sci. 2008 Sep;1(2):136-41
pubmed: 20443834
Intest Res. 2019 Jul;17(3):317-329
pubmed: 31085968
Int J Surg. 2021 Dec;96:106165
pubmed: 34774726